App-Quantinova.ai

Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study

A. David Burden - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis 14, pustular

Interleukin

Long-term Efficacy and Safety of Risankizumab (RZB) for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Beyond 4 Years of Follow-up

Kim A Papp - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Risankizumab

Dupilumab Significantly Improves Sleep Disturbance in Adults with Moderate-to-Severe Atopic Dermatitis: Results of the DUPISTAD study

Joseph F. Merola - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Maintenance of Skin Clearance in a Long-term Open-label Study of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Participants With Prior Use of Topical Treatments

Linda Stein Gold - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Halobetasol propionate

Persistence and adherence to ixekizumab treatment in patients with moderate-to-severe psoriasis before and during COVID-19 pandemic: Results from the Canadian Patient Support Program

Wayne Gulliver - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

LY2439821

Treatment with Amlitelimab (KY1005, SAR445229) - a novel non-depleting anti-OX40Ligand (OX40L) mAb - reduces IL-13 serum levels in a Phase 2a randomised placebo-controlled trial in patients with moderate to severe Atopic Dermatitis.

Stephan Weidinger - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

KY1005

Bimekizumab versus secukinumab in plaque psoriasis: Reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase 3b trial

Matthias Augustin - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

bimekizumab

Malignancy Rates Through 5 Years of Follow-up in Guselkumab-treated Patients With Moderate to Severe Psoriasis: Results From the VOYAGE 1 and 2 Trials and Comparisons to General Populations

Andrew Blauvelt - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cervical cancer

guselkumab (IV)

Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 trials BRAVE-AA1 and BRAVE-AA2

Brett King - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Baricitinib

Baseline characteristics and comorbid conditions in patients with moderate-to-severe plaque psoriasis enrolled in the Psoriasis Study of Health Outcomes (PSoHO)

LluÃs Puig - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Interleukin

Impact of risankizumab on improving health-related quality of life, work productivity, and reducing fatigue among patients with active psoriatic arthritis: A pooled analysis of two Phase 3 clinical trials

Lars Erik Kristensen - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Risankizumab

Simultaneous Nail and Skin Clearance in Five Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis

Boni E. Elewski - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

LY2439821

Enthesitis in Patients With Psoriatic Arthritis Treated With Secukinumab or Adalimumab: a Post Hoc Analysis of EXCEED

Gurjit S. Kaeley - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

secukinumab

Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Use of Standard-of-care Antihistamines: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)

Marcus Maurer - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Dupilumab

Clinically significant improvements in patient-reported outcomes (PROs) in patients with a generalized pustular psoriasis (GPP) flare treated with spesolimab

Alexander A. Navarini - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Psoriasis 14, pustular

N/A

Improving clinical trial experience for patients and investigators through a simulated trial in palmoplantar pustulosis (PPP)

David Trigos - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Psoriasis 14, pustular

N/A

Prevalence, comorbidities and mortality of generalized pustular psoriasis (GPP): a literature review

Manuelle Viguier - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis 14, pustular

N/A

Social Relationships, Sexual Difficulty, and the Impact of Treatment With Guselkumab Versus Adalimumab in Men and Women With Psoriasis: Results From VOYAGE 1 and 2

April Armstrong - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Adalimumab

Ixekizumab achieved and sustained nail psoriasis resolution regardless of disease severity through 5 years: Results from Uncover-3

Alexander Egeberg - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

LY2439821

Safety of Guselkumab in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Clinical Studies

Mark Lebwohl - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

guselkumab (IV)

Filters

45280 Abstracts